Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-centre, Open Label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib in Patients With Advanced/Metastatic Ocular/Uveal Melanoma

NCT06717126 is registered in ClinicalTrials.gov with iOnctura as lead sponsor.

NCT NCT06717126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06717126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-centre, Open Label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib in Patients With Advanced/Metastatic Ocular/Uveal Melanoma
Lead sponsor
iOnctura
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 27, 2025
Completion date
December 31, 2028
Enrollment
85 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ocular melanoma, uveal melanoma